ClinicalTrials.gg

Program

tucidinostat

Also written as “Chidamide”, “Tucidinostat” and “HBI-8000”.

Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Melanoma · Breast Neoplasms · Lymphoma, Non-Hodgkin, led by 4 companies.

Furthest: phase 3, since Jun 17, 201519 company-led studies, 5 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chipscreen Biosciences92 open or runningphase 3since Jun 17, 2015Apr 12, 2013May 31, 2028phase 3 · NCT06497985
HUYABIO International, LLC.71 open or runningphase 3since Dec 7, 2020Oct 5, 2015none ahead
Great Novel Therapeutics Biotech & Medicals21 open or runningphase 2since Feb 7, 2023Feb 7, 2023Jun 2027phase 2 · NCT05833724
Jiangsu HengRui Medicine11 open or runningphase 3since Nov 5, 2023Nov 5, 2023none ahead

Also a collaborator on its studies: Bristol-Myers Squibb and iqvia-pty-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Apr 12, 2013.

  1. Mar 15, 2016Phase 2 study in MelanomaHUYABIO International, LLC. · NCT02718066 · 96 enrolled · United States
  2. Jun 17, 2016Phase 1 study in Lymphoma, T-Cell, PeripheralChipscreen Biosciences · NCT02809573 · 30 enrolled · China
  3. Nov 1, 20162 phase 2 studiesHUYABIO International, LLC. · NCT02955589, NCT02953652
  4. May 30, 2019Phase 2 study in Lymphoma, Non-HodgkinChipscreen Biosciences · NCT03974243 · 9 enrolled · China
  5. Jan 14, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseChipscreen Biosciences · NCT04231448 · 423 enrolled · China
  6. Dec 7, 2020Phase 3 study in MelanomaHUYABIO International, LLC. · NCT04674683 · 450 enrolled · United States, Australia, Austria and more
  7. Sep 27, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungChipscreen Biosciences · NCT05068427 · 34 enrolled · China
  8. Nov 19, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungHUYABIO International, LLC. · NCT05141357 · 5 enrolled · United States
  9. Aug 23, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungChipscreen Biosciences · NCT05519865 · 118 enrolled · China
  10. Feb 7, 2023Great Novel Therapeutics Biotech & Medicals's first study: phase 2 study in Carcinoma, HepatocellularNew to Great Novel Therapeutics Biotech & MedicalsGreat Novel Therapeutics Biotech & Medicals · NCT05770882 · 7 enrolled · Taiwan
  11. Apr 17, 2023Phase 2 study in RecurrenceGreat Novel Therapeutics Biotech & Medicals · NCT05833724 · 33 planned · Taiwan
  12. Nov 5, 2023Jiangsu HengRui Medicine's first study: phase 3 study in RecurrenceNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06122389 · 130 planned · China
  13. Jun 28, 2024Phase 3 study in Colorectal NeoplasmsChipscreen Biosciences · NCT06497985 · 430 planned · China
  14. Apr 25, 2025Phase 3 study in Lymphoma, T-Cell, PeripheralChipscreen Biosciences · NCT06947967 · 224 planned · China

Ahead

  1. Jun 2027Primary completion: phase 2 study in RecurrenceGreat Novel Therapeutics Biotech & Medicals · NCT05833724
  2. May 31, 2028Primary completion: phase 3 study in Colorectal NeoplasmsChipscreen Biosciences · NCT06497985
  3. Dec 2032Primary completion: phase 3 study in Lymphoma, T-Cell, PeripheralChipscreen Biosciences · NCT06947967

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06947967Lymphoma, T-Cell, Peripheral · China3RecruitingChipscreen BiosciencesDec 2032224
NCT06497985Colorectal Neoplasms · China3RecruitingChipscreen BiosciencesMay 31, 2028430
NCT06122389Recurrence · China3RecruitingJiangsu HengRui MedicineMay 2026130
NCT05833724Recurrence · Taiwan2RecruitingGreat Novel Therapeutics Biotech & MedicalsJun 202733
NCT05770882Carcinoma, Hepatocellular · Taiwan2TerminatedGreat Novel Therapeutics Biotech & MedicalsJan 17, 20257
NCT05519865Carcinoma, Non-Small-Cell Lung · China2CompletedChipscreen BiosciencesNov 18, 2024118
NCT05141357Carcinoma, Non-Small-Cell Lung · United States2TerminatedHUYABIO International, LLC.Apr 19, 20235
NCT05068427Carcinoma, Non-Small-Cell Lung · China2CompletedChipscreen BiosciencesFeb 23, 202334
NCT04674683Melanoma · United States, Australia, Austria and more3Active, not recruitingHUYABIO International, LLC.Jul 2026450
NCT04231448Lymphoma, Large B-Cell, Diffuse · China3CompletedChipscreen BiosciencesJan 10, 2023423
NCT03974243Lymphoma, Non-Hodgkin · China2CompletedChipscreen BiosciencesDec 31, 20219
NCT02955589Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Japan2CompletedHUYABIO International, LLC.Dec 201823
NCT02953652Lymphoma, T-Cell, Peripheral · Japan, Korea, Republic of2CompletedHUYABIO International, LLC.Feb 17, 202255
NCT02809573Lymphoma, T-Cell, Peripheral · China1CompletedChipscreen BiosciencesJan 8, 201930
NCT02718066Melanoma · United States2CompletedHUYABIO International, LLC.Dec 12, 202396
NCT02697552Lymphoma, Non-Hodgkin · Japan1CompletedHUYABIO International, LLC.Oct 201613
NCT02569489Breast Neoplasms1WithdrawnHUYABIO International, LLC.Dec 20150
NCT02482753Breast Neoplasms · China3CompletedChipscreen BiosciencesMar 2018365
NCT01836679Carcinoma, Non-Small-Cell Lung · China2CompletedChipscreen BiosciencesMay 2015124

How it is read

Names in the registry

  • “Chidamide”, 7 entries
  • “Tucidinostat”, 4 entries
  • “HBI-8000”, 4 entries
  • “HBI-8000 in combination with nivolumab”, 2 entries
  • “SHR2554 analog tablets; Chidamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
tucidinostat (Chipscreen Biosciences): development program | ClinicalTrials.gg